

Dan G Duda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/988615/publications.pdf>

Version: 2024-02-01

256
papers

30,296
citations

5876

81
h-index

4870

168
g-index

267
all docs

267
docs citations

267
times ranked

33324
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct evidence that the VEGF-specific antibody bevacizumab has antivasular effects in human rectal cancer. <i>Nature Medicine</i> , 2004, 10, 145-147.	15.2	1,852
2	AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. <i>Cancer Cell</i> , 2007, 11, 83-95.	7.7	1,675
3	Normalization of the Vasculature for Treatment of Cancer and Other Diseases. <i>Physiological Reviews</i> , 2011, 91, 1071-1121.	13.1	1,275
4	Angiogenesis in brain tumours. <i>Nature Reviews Neuroscience</i> , 2007, 8, 610-622.	4.9	1,229
5	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 325-340.	12.5	1,192
6	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 24-40.	4.3	968
7	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17561-17566.	3.3	800
8	Engineering vascularized tissue. <i>Nature Biotechnology</i> , 2005, 23, 821-823.	9.4	712
9	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
10	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 1116-1135.	7.7	637
11	Biomarkers of response and resistance to antiangiogenic therapy. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 327-338.	12.5	541
12	Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. <i>Cancer Research</i> , 2013, 73, 2943-2948.	0.4	535
13	Malignant cells facilitate lung metastasis by bringing their own soil. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 21677-21682.	3.3	505
14	Phase II Study of Cediranib, an Oral Pan-VEGF Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2817-2823.	0.8	489
15	Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3020-3026.	0.8	487
16	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
17	Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3027-3035.	0.8	467
18	HCC and angiogenesis: possible targets and future directions. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 292-301.	12.5	453

#	ARTICLE	IF	CITATIONS
19	Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. <i>Nature Medicine</i> , 2005, 11, 678-682.	15.2	419
20	Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 8136-8139.	0.8	410
21	CXCL12 (SDF1 \pm)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?. <i>Clinical Cancer Research</i> , 2011, 17, 2074-2080.	3.2	377
22	Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models. <i>Microcirculation</i> , 2010, 17, 206-225.	1.0	376
23	A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. <i>Cancer Research</i> , 2009, 69, 5296-5300.	0.4	369
24	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. <i>Hepatology</i> , 2015, 61, 1591-1602.	3.6	355
25	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	3.4	353
26	Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. <i>Blood</i> , 2008, 111, 1302-1305.	0.6	311
27	Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 855-860.	3.3	308
28	Paracrine Regulation of Angiogenesis and Adipocyte Differentiation During In Vivo Adipogenesis. <i>Circulation Research</i> , 2003, 93, e88-97.	2.0	305
29	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19059-19064.	3.3	303
30	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4476-4481.	3.3	287
31	Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice. <i>Journal of Clinical Oncology</i> , 2009, 27, 2542-2552.	0.8	285
32	A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. <i>Nature Protocols</i> , 2007, 2, 805-810.	5.5	265
33	Recruitment of Myeloid but not Endothelial Precursor Cells Facilitates Tumor Regrowth after Local Irradiation. <i>Cancer Research</i> , 2010, 70, 5679-5685.	0.4	253
34	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4470-4475.	3.3	251
35	Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 1247-1261.	3.6	247
36	Role of eNOS in neovascularization: NO for endothelial progenitor cells. <i>Trends in Molecular Medicine</i> , 2004, 10, 143-145.	3.5	219

#	ARTICLE	IF	CITATIONS
37	The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 113.	3.4	213
38	Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. <i>Hepatology</i> , 2014, 60, 1776-1782.	3.6	210
39	Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. <i>Cell</i> , 2013, 152, 1065-1076.	13.5	209
40	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14325-14330.	3.3	206
41	Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013, 15, 1079-1087.	0.6	205
42	Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. <i>Angiogenesis</i> , 2003, 6, 15-24.	3.7	191
43	Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape. <i>Cancer Research</i> , 2011, 71, 19-28.	0.4	186
44	Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. <i>Science Translational Medicine</i> , 2016, 8, 360ra135.	5.8	184
45	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. <i>Hepatology</i> , 2014, 59, 1435-1447.	3.6	178
46	Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	177
47	VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 229-236.	12.5	175
48	Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3725-3730.	3.3	169
49	Combining microenvironment normalization strategies to improve cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3728-3737.	3.3	163
50	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	153
51	Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 α , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer. <i>Cancer Research</i> , 2009, 69, 7905-7910.	0.4	150
52	Fatty acid synthesis is required for breast cancer brain metastasis. <i>Nature Cancer</i> , 2021, 2, 414-428.	5.7	147
53	Lessons From Anti-VEGF and Anti-VEGF Receptor Trials in Patients With Glioblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1197-1213.	0.8	145
54	A protein and mRNA expression-based classification of gastric cancer. <i>Modern Pathology</i> , 2016, 29, 772-784.	2.9	142

#	ARTICLE	IF	CITATIONS
55	Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. <i>Blood</i> , 2006, 107, 2774-2776.	0.6	141
56	A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6614-6623.	3.2	139
57	Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12774-12779.	3.3	137
58	Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers. <i>Journal of Clinical Oncology</i> , 2007, 25, 4033-4042.	0.8	130
59	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
60	VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. <i>Trends in Molecular Medicine</i> , 2007, 13, 223-230.	3.5	124
61	Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. <i>Immunotherapy</i> , 2016, 8, 299-313.	1.0	124
62	Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1449-1453.	0.8	121
63	Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a027094.	2.9	119
64	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1547-1552.	3.3	115
65	Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1350-1355.	3.3	109
66	PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. <i>Clinical Cancer Research</i> , 2016, 22, 2993-3004.	3.2	109
67	Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as <i>in Vivo</i> Two-Photon Oxygen Sensors. <i>Journal of the American Chemical Society</i> , 2015, 137, 9832-9842.	6.6	104
68	Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1188-1201.	3.0	101
69	A Phase I/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 830-838.	0.4	101
70	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. <i>Radiotherapy and Oncology</i> , 2016, 120, 185-194.	0.3	99
71	Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	97
72	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in <i>Opisthorchis viverrini</i> Associated Cholangiocarcinoma. <i>EBioMedicine</i> , 2016, 8, 195-202.	2.7	94

#	ARTICLE	IF	CITATIONS
73	Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. <i>Nature Communications</i> , 2022, 13, 758.	5.8	94
74	Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. <i>Oncogene</i> , 2003, 22, 6857-6864.	2.6	92
75	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2 Associated Vestibular Schwannomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 1669-1675.	0.8	92
76	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. <i>Cancer</i> , 2017, 123, 1979-1988.	2.0	92
77	Benefits of Vascular Normalization Are Dose and Time Dependent Letter. <i>Cancer Research</i> , 2013, 73, 7144-7146.	0.4	89
78	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	89
79	Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. , 2020, 8, e001435.		87
80	C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 302-307.	3.3	85
81	Combined Vascular Endothelial Growth Factor Targeted Therapy and Radiotherapy for Rectal Cancer: Theory and Clinical Practice. <i>Seminars in Oncology</i> , 2006, 33, S35-S40.	0.8	84
82	Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2010, 15, 577-583.	1.9	84
83	Blockade of VEGFR2 and Not VEGFR1 Can Limit Diet-Induced Fat Tissue Expansion: Role of Local versus Bone Marrow-Derived Endothelial Cells. <i>PLoS ONE</i> , 2009, 4, e4974.	1.1	83
84	Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2011, 103, 325-332.	1.4	82
85	An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. <i>Nature Protocols</i> , 2015, 10, 1264-1274.	5.5	82
86	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	3.2	79
87	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. <i>Oncologist</i> , 2017, 22, 25-32.	1.9	79
88	Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1081-1090.	0.4	77
89	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	0.8	73
90	Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. <i>Theranostics</i> , 2018, 8, 894-905.	4.6	72

#	ARTICLE	IF	CITATIONS
91	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 603-610.	1.4	69
92	VEGFR1-activity-independent metastasis formation. <i>Nature</i> , 2009, 461, E4-E4.	13.7	68
93	An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients With Ductal Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2012, 41, 1001-1007.	0.5	68
94	Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor. <i>Pancreas</i> , 2002, 25, 111-121.	0.5	66
95	Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. <i>Clinical Cancer Research</i> , 2013, 19, 1557-1566.	3.2	65
96	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 80-89.	3.2	62
97	Platelet-derived growth factor receptor- β^2 in Gorham's disease. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 693-697.	4.3	60
98	Role of bone marrow-derived cells in tumor angiogenesis and treatment. <i>Cancer Cell</i> , 2003, 3, 515-516.	7.7	59
99	Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?. <i>Journal of the National Cancer Institute</i> , 2012, 104, 899-905.	3.0	58
100	Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	56
101	Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. <i>Scientific Reports</i> , 2017, 7, 44123.	1.6	56
102	A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2010, 15, 845-851.	1.9	55
103	Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 316-321.	4.3	52
104	Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?. <i>Journal of Clinical Oncology</i> , 2010, 28, 183-185.	0.8	52
105	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1386-1392.	0.6	50
106	Differential Transplantability of Tumor-Associated Stromal Cells. <i>Cancer Research</i> , 2004, 64, 5920-5924.	0.4	49
107	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	1.6	49
108	Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e38231.	1.1	48

#	ARTICLE	IF	CITATIONS
109	Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 206-212.	3.2	48
110	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. <i>Nature Biotechnology</i> , 2020, 38, 420-425.	9.4	48
111	VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation. <i>PLoS ONE</i> , 2009, 4, e6525.	1.1	48
112	Changes in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer. <i>Oncologist</i> , 2012, 17, 212-219.	1.9	47
113	Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. <i>Journal of Hematology and Oncology</i> , 2013, 6, 51.	6.9	47
114	Familial Gastric Cancers. <i>Oncologist</i> , 2015, 20, 1365-1377.	1.9	46
115	Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 607-612.	0.5	45
116	Paradoxical Effects of PDGF-BB Overexpression in Endothelial Cells on Engineered Blood Vessels In Vivo. <i>American Journal of Pathology</i> , 2009, 175, 294-302.	1.9	43
117	Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	40
118	Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). <i>PLoS ONE</i> , 2012, 7, e26331.	1.1	39
119	Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. , 2012, 2012, 1-11.		37
120	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 4643-4649.	3.2	37
121	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6158-6167.	3.2	37
122	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. <i>JCO Global Oncology</i> , 2020, 6, 628-638.	0.8	35
123	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. <i>Gut</i> , 2022, 71, 185-193.	6.1	34
124	Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 263-268.	1.0	33
125	Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 39-49.	6.0	32
126	Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. <i>Comparative Medicine</i> , 2008, 58, 253-63.	0.4	32

#	ARTICLE	IF	CITATIONS
127	Premetastatic Lung "Niche" Is Vascular Endothelial Growth Factor Receptor 1 Activation Required?. <i>Cancer Research</i> , 2010, 70, 5670-5673.	0.4	31
128	Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value. <i>Clinical Cancer Research</i> , 2011, 17, 918-927.	3.2	29
129	Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1222-1225.	0.4	29
130	Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy. <i>American Journal of Roentgenology</i> , 2016, 206, 987-993.	1.0	28
131	Antiangiogenic agents for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1895-1908.	1.9	26
132	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 113-123.	1.1	26
133	Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 1051.	3.4	25
134	Vascular diseases await translation of blood vessels engineered from stem cells. <i>Science Translational Medicine</i> , 2015, 7, 309rv6.	5.8	24
135	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.4	24
136	CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression. <i>American Journal of Roentgenology</i> , 2015, 204, W11-W18.	1.0	23
137	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. <i>Cancer Medicine</i> , 2019, 8, 5988-5994.	1.3	23
138	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 62.	2.3	23
139	Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1301-1305.	3.0	22
140	The Antiangiogenesis Effect of Interleukin 12 During Early Growth of Human Pancreatic Cancer in SCID Mice. <i>Pancreas</i> , 2000, 20, 227-233.	0.5	21
141	Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Malignant Ovarian Carcinoma. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 26-33.	0.2	21
142	A transient parabiosis skin transplantation model in mice. <i>Nature Protocols</i> , 2012, 7, 763-770.	5.5	21
143	A cerebellar window for intravital imaging of normal and disease states in mice. <i>Nature Protocols</i> , 2017, 12, 2251-2262.	5.5	21
144	Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. <i>American Journal of Cancer Research</i> , 2011, 1, 144-54.	1.4	21

#	ARTICLE	IF	CITATIONS
145	Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. <i>Npj Precision Oncology</i> , 2018, 2, 22.	2.3	20
146	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20
147	Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 234-242.	1.5	19
148	Characterization of Functional Transient Receptor Potential Melastatin 8 Channels in Human Pancreatic Ductal Adenocarcinoma Cells. <i>Pancreas</i> , 2014, 43, 795-800.	0.5	19
149	Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2020, 12, 1275.	1.7	19
150	Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. <i>Radiation Oncology</i> , 2021, 16, 48.	1.2	19
151	Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. <i>Nature Protocols</i> , 2012, 7, 756-762.	5.5	17
152	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	16
153	Targeted therapy in rectal cancer. <i>Oncology</i> , 2007, 21, 1055-65; discussion 1065, 1070, 1075 passim.	0.4	16
154	VEGFR2 ⁺ PDGFR ²⁺ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI). <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 3720-3729.	1.6	15
155	Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling?. <i>Journal of the National Cancer Institute</i> , 2013, 105, 762-765.	3.0	15
156	Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?. <i>Cancer Research</i> , 2019, 79, 2104-2106.	0.4	15
157	Gene therapy for pancreatic cancer based on genetic characterization of the disease. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2002, 9, 32-38.	2.0	14
158	FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. <i>Cancer</i> , 2019, 125, 2213-2221.	2.0	14
159	Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism. <i>Medical Hypotheses</i> , 2014, 83, 477-481.	0.8	13
160	Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol. <i>Endoscopic Ultrasound</i> , 2019, 8, 235.	0.6	13
161	Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 4.	2.3	12
162	Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow. <i>Journal of Clinical Investigation</i> , 2005, 115, 596-598.	3.9	12

#	ARTICLE	IF	CITATIONS
163	VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway. <i>Journal of Translational Medicine</i> , 2022, 20, 212.	1.8	12
164	The Role of Chromosome 18 Abnormalities in the Progression of Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2004, 28, 311-316.	0.5	11
165	An isolated tumor perfusion model in mice. <i>Nature Protocols</i> , 2012, 7, 749-755.	5.5	11
166	Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. <i>Scientific Reports</i> , 2018, 8, 17062.	1.6	11
167	Is vasculogenesis crucial for the regrowth of irradiated tumours?. <i>Nature Reviews Cancer</i> , 2011, 11, 532-532.	12.8	11
168	Role of stromal cell-derived factor 1 α pathway in bone metastatic prostate cancer. <i>Journal of Biomedical Research</i> , 2016, 30, 181-5.	0.7	11
169	IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 488-488.	0.8	11
170	A protocol for a lung neovascularization model in rodents. <i>Nature Protocols</i> , 2008, 3, 378-387.	5.5	10
171	Is vasculogenesis crucial for the regrowth of irradiated tumours?. <i>Nature Reviews Cancer</i> , 2011, 11, 532-532.	12.8	10
172	Next generation metronomic chemotherapy” report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6”8 May 2016, Mumbai. <i>Ecanermedscience</i> , 2016, 10, 689.	0.6	10
173	A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. <i>Nature Protocols</i> , 2008, 3, 388-397.	5.5	9
174	Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma ” an auto-commentary on clinical potential and future development. <i>Oncolmmunology</i> , 2015, 4, e1029703.	2.1	9
175	A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1026-1026.	0.8	9
176	Visualizing anti-tumor immune responses in vivo. <i>DMM Disease Models and Mechanisms</i> , 2009, 2, 107-110.	1.2	8
177	Seeds and Soil: Unraveling the Role of Local Tumor Stroma in Distant Metastasis. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju187-dju187.	3.0	8
178	Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa157.	0.4	8
179	Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. <i>EBioMedicine</i> , 2020, 52, 102644.	2.7	8
180	Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. <i>Cancer Research</i> , 2008, 68, LB-247-LB-247.	0.4	7

#	ARTICLE	IF	CITATIONS
181	From the Guest Editors. Cancer Journal (Sudbury, Mass), 2015, 21, 235-236.	1.0	6
182	Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.. Journal of Clinical Oncology, 2020, 38, 486-486.	0.8	6
183	Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?. OncoTargets and Therapy, 2017, Volume 10, 1403-1412.	1.0	5
184	Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers. JCO Clinical Cancer Informatics, 2021, 5, 315-325.	1.0	5
185	Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. Cancers, 2021, 13, 4919.	1.7	5
186	Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. Cancers, 2021, 13, 5725.	1.7	5
187	A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clinical Cancer Research, 2022, 28, 3950-3957.	3.2	5
188	Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition. Clinical Cancer Research, 2022, 28, 3076-3090.	3.2	4
189	Reply to S.J. Faivre et al. Journal of Clinical Oncology, 2009, 27, e251-e252.	0.8	3
190	Tumor Microenvironment. , 2020, , 108-126.e7.		3
191	Normalization of Tumor Vasculature and Microenvironment. , 2008, , 273-281.		3
192	Vascular and Interstitial Biology of Tumors. , 2014, , 108-126.e5.		3
193	Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1093-1093.	0.8	3
194	Lessons From 30 Years of Teaching About the Microenvironment of Tumors. Cancer Journal (Sudbury,) Tj ETQq0 0 Q rgBT /Overlock 10 T	1.0	2
195	Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncology, The, 2015, 16, 882-883.	5.1	2
196	Normalization of Tumor Vasculature and Microenvironment. , 2008, , 261-276.		2
197	Anti-angiogenics and Radiation Therapy. , 2017, , 1-10.		2
198	Vascular and Interstitial Biology of Tumors. , 2008, , 105-124.		2

#	ARTICLE	IF	CITATIONS
199	Abstract LB-344: Vascular normalization as an emerging strategy to enhance cancer immunotherapy.. Cancer Research, 2013, 73, LB-344-LB-344.	0.4	2
200	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2014, 32, 2031-2031.	0.8	2
201	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2032-2032.	0.8	2
202	Immune checkpoint blockade (ICB) response evaluation with MRI/MR elastography (MRE) in surgical and nonsurgical patients with HCC.. Journal of Clinical Oncology, 2020, 38, 480-480.	0.8	2
203	A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1080-1080.	0.8	2
204	Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. , 2016, , .		2
205	Gene therapy for pancreatic cancer using soluble VEGF receptor. Gastroenterology, 2000, 118, A1040.	0.6	1
206	Anti-angiogenesis effect of p53-target gene, BAI1 on pancreatic cancer. Gastroenterology, 2000, 118, A1043.	0.6	1
207	Endothelial cellâ€‘based therapy for hematopoiesis. Blood, 2007, 109, 2272-2273.	0.6	1
208	New Perspective on the Treatment of Intractable Gastrointestinal Cancers: Role of Combination Therapies. Keio Journal of Medicine, 2017, 66, 72-72.	0.5	1
209	Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?. Hepatology, 2018, 67, 826-828.	3.6	1
210	Combined Angiotensin Receptor Blocker Losartan and the CXCR4 Inhibitor AMD3100 Increases the Efficacy of Radiotherapy in a Metastatic Osteosarcoma Mouse Model. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	1
211	Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy. Clinical and Translational Radiation Oncology, 2019, 18, 113-119.	0.9	1
212	Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy. Circulation Research, 2020, 127, 724-726.	2.0	1
213	Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer. , 2008, , .		1
214	Abstract LB-346: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. , 2016, , .		1
215	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma.. Journal of Clinical Oncology, 2012, 30, 2010-2010.	0.8	1
216	Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147).. Journal of Clinical Oncology, 2012, 30, 4112-4112.	0.8	1

#	ARTICLE	IF	CITATIONS
217	A comparative study of circulating biomarkers of anti-VEGF therapy in phase II trials in advanced hepatocellular carcinoma (HCC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 2543-2543.	0.8	1
218	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2015, 33, TPS2080-TPS2080.	0.8	1
219	Circulating biomarkers in a phase II study of hypofractionated proton beam therapy (H-PBT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2016, 34, 4083-4083.	0.8	1
220	Abstract C1: Functional normalization of the breast cancer vasculature through activation of Tie2 using a vascular-endothelial protein tyrosine phosphatase inhibitor.. Molecular Cancer Therapeutics, 2013, 12, C1-C1.	1.9	1
221	Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers. International Journal of Molecular Sciences, 2022, 23, 1926.	1.8	1
222	American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer. IDrugs: the Investigational Drugs Journal, 2007, 10, 366-9.	0.7	1
223	Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?. Gut, 0, , gutjnl-2022-327782.	6.1	1
224	Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3454-E3454.	3.3	0
225	Controlling Tumor Microenvironment by the Antiangiogenesis Strategy. , 2001, , 287-289.		0
226	Phenotypic and functional characterization of proangiogenic monocytes. FASEB Journal, 2008, 22, 238.7.	0.2	0
227	Abstract LB-213: Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. , 2010, , .		0
228	Abstract LB-76: A study of neoadjuvant bevacizumab with standard chemoradiation versus chemoradiation alone in locally advanced rectal cancer. , 2010, , .		0
229	Antiangiogenesis. , 2011, , 203-207.		0
230	Abstract A67: Reconditioning the tumor immune microenvironment for a breast cancer vaccine therapy.. , 2013, , .		0
231	Biomarkers of Response and Resistance to Anti-angiogenic Treatment. , 2013, , 181-198.		0
232	Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo. , 2013, , .		0
233	Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2013, 31, 4125-4125.	0.8	0
234	Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2013, 31, 4047-4047.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 1065-1065.	0.8	0
236	Antiangiogenesis. , 2014, , 262-268.		0
237	Antiangiogenesis. , 2014, , 1-8.		0
238	A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, TPS4157-TPS4157.	0.8	0
239	Abstract IA17: Targeting placental growth factor/ neuropilin-1 pathway inhibits growth and spread of medulloblastoma. , 2014, , .		0
240	Abstract B79: CXCR4 inhibition facilitates anti-PD-1 immunotherapy by reprogramming the tumor microenvironment during sorafenib treatment in hepatocellular carcinoma. , 2015, , .		0
241	Abstract B03: Formation of lymph node metastases is not angiogenesis dependent. , 2016, , .		0
242	Abstract PR06: VEGF-targeted therapy induces extracellular matrix remodeling and increases mechanical barriers to therapy in colorectal cancer liver metastases. , 2017, , .		0
243	Anti-VEGFR Therapy as a Partner for Immune-Based Therapy Approaches in HCC. , 2017, , 85-101.		0
244	Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. , 2017, , .		0
245	A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, TPS1119-TPS1119.	0.8	0
246	A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2018, 36, 1026-1026.	0.8	0
247	Anti-angiogenics and Radiation Therapy. , 2019, , 349-358.		0
248	IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.. Journal of Clinical Oncology, 2020, 38, e16660-e16660.	0.8	0
249	The role of ALBI and IGF-CTP score in refining prognostication of HCC.. Journal of Clinical Oncology, 2020, 38, e16659-e16659.	0.8	0
250	Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy.. Journal of Clinical Oncology, 2020, 38, e16626-e16626.	0.8	0
251	Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment. , 2008, , 577-592.		0
252	Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?. Oncology, 2012, 26, 741-3.	0.4	0

#	ARTICLE	IF	CITATIONS
253	Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. , 2021, , .		0
254	Abstract P061: Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits the efficacy of immune checkpoint blockade. , 2022, , .		0
255	Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. JCO Clinical Cancer Informatics, 2022, 6, e2100169.	1.0	0
256	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. EJHaem, 0, , .	0.4	0